1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
About Systemic Psoriasis Therapeutics
Psoriasis is a chronic skin disease affecting about 2% of the world’s population. Different forms of psoriasis include plaque, inverse, pustular, and guttate psoriasis.
The analysts forecast the Global Systemic Psoriasis Therapeutics Market to grow at a CAGR of 10.07% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the systemic psoriasis therapeutics market. To calculate the market size, the report considers the revenue generated from sale of different systemic psoriasis therapeutics.
The market is divided into the following segments based on geography:
Key vendors
Psoriasis is a chronic skin disease affecting about 2% of the world’s population. Different forms of psoriasis include plaque, inverse, pustular, and guttate psoriasis.
The analysts forecast the Global Systemic Psoriasis Therapeutics Market to grow at a CAGR of 10.07% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the systemic psoriasis therapeutics market. To calculate the market size, the report considers the revenue generated from sale of different systemic psoriasis therapeutics.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
Key vendors
- AbbVie
- Amgen
- Celgene
- Johnson & Johnson
- Need for affordable therapies
- For a full, detailed list, view the full report
- Patent expiry of drugs
- For a full, detailed list, view the full report
- Rise in cost of systemic psoriasis therapy
- For a full, detailed list, view the full report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Note: Product cover images may vary from those shown
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
PART 13: REGIONAL LANDSCAPE
PART 15: DRIVERS AND CHALLENGES
Exhibit 01: Parent market
Exhibit 02: Global dermatological drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global systemic psoriasis therapeutics market – Market size and forecast 2017-2022 ($ bn)
Exhibit 09: Global systemic psoriasis therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2017
Exhibit 17: Relationship between need, supply, and demand
Exhibit 18: List of biosimilars approved by FDA for psoriasis
Exhibit 19: List of biosimilars approved by European Medicines Agency (EMA) for psoriasis
Exhibit 20: List of biologics and small molecules (phase II and III in pipeline) and MOA
Exhibit 21: List of biosimilars (phase II and III in pipeline) and MOA
Exhibit 22: Biologics targeting IL-23 and IL-17
Exhibit 23: Global systemic psoriasis therapeutics market by product – Market share 2017-2022 (%)
Exhibit 24: Comparison by product
Exhibit 25: Global systemic psoriasis therapeutics market by small molecules – Market size and forecast 2017-2022 ($ bn)
Exhibit 26: Global systemic psoriasis therapeutics market by small molecules – Year-over-year growth 2018-2022 (%)
Exhibit 27: Global systemic psoriasis therapeutics market by biologics – Market size and forecast 2017-2022 ($ bn)
Exhibit 28: Global systemic psoriasis therapeutics market by biologics – Year-over-year growth 2018-2022 (%)
Exhibit 29: Market opportunity by product
Exhibit 30: Customer landscape
Exhibit 31: Global systemic psoriasis therapeutics market by region – Market share 2017-2022 (%)
Exhibit 32: Regional comparison
Exhibit 33: Global systemic psoriasis therapeutics market in Americas – Market size and forecast 2017-2022 ($ bn)
Exhibit 34: Global systemic psoriasis therapeutics market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top three countries in Americas
Exhibit 36: Global systemic psoriasis therapeutics market in EMEA – Market size and forecast 2017-2022 ($ bn)
Exhibit 37: Global systemic psoriasis therapeutics market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top three countries in EMEA
Exhibit 39: Global systemic psoriasis therapeutics market in APAC – Market size and forecast 2017-2022 ($ bn)
Exhibit 40: Global systemic psoriasis therapeutics market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 41: Top three countries in APAC
Exhibit 42: Market opportunity
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: AbbVie overview
Exhibit 49: AbbVie – Business segments
Exhibit 50: AbbVie – Organizational developments
Exhibit 51: AbbVie – Geographic focus
Exhibit 52: AbbVie – Segment focus
Exhibit 53: AbbVie – Key offerings
Exhibit 54: Amgen overview
Exhibit 55: Amgen – Business Segments
Exhibit 56: Amgen – Organizational developments
Exhibit 57: Amgen – Geographic focus
Exhibit 58: Amgen – Segment focus
Exhibit 59: Amgen – Key offerings
Exhibit 60: Celgene overview
Exhibit 61: Celgene – Business segments
Exhibit 62: Celgene – Organizational developments
Exhibit 63: Celgene – Geographic focus
Exhibit 64: Celgene – Segment focus
Exhibit 65: Celgene – Key offerings
Exhibit 66: Johnson & Johnson overview
Exhibit 67: Johnson & Johnson – Business segments
Exhibit 68: Johnson & Johnson – Organizational developments
Exhibit 69: Johnson & Johnson – Geographic focus
Exhibit 70: Johnson & Johnson – Segment focus
Exhibit 71: Johnson & Johnson – Key offerings
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Pipeline analysis
- Discontinued psoriasis therapies
- Segmentation by product
- Comparison by product
- Small molecules – Market size and forecast 2017-2022
- Biologics – Market size and forecast 2017-2022
- Market opportunity by product
- Segmentation by ROA
- Oral
- Parenteral
- Segmentation by severity of disease
- Segmentation by end-user
- Hospitals
- Retail pharmacies
PART 13: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas – Market size and forecast 2017-2022
- EMEA – Market size and forecast 2017-2022
- APAC – Market size and forecast 2017-2022
- Market opportunity
PART 15: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Rise in cost of systemic psoriasis therapy
- Introduction of biologics
- Gene therapy for psoriasis
- Use of combination therapy
- Research in precision healthcare infrastructure
- Overview
- Landscape disruption
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AbbVie
- Amgen
- Celgene
- Johnson & Johnson
- List of abbreviations
Exhibit 01: Parent market
Exhibit 02: Global dermatological drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global systemic psoriasis therapeutics market – Market size and forecast 2017-2022 ($ bn)
Exhibit 09: Global systemic psoriasis therapeutics market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2017
Exhibit 17: Relationship between need, supply, and demand
Exhibit 18: List of biosimilars approved by FDA for psoriasis
Exhibit 19: List of biosimilars approved by European Medicines Agency (EMA) for psoriasis
Exhibit 20: List of biologics and small molecules (phase II and III in pipeline) and MOA
Exhibit 21: List of biosimilars (phase II and III in pipeline) and MOA
Exhibit 22: Biologics targeting IL-23 and IL-17
Exhibit 23: Global systemic psoriasis therapeutics market by product – Market share 2017-2022 (%)
Exhibit 24: Comparison by product
Exhibit 25: Global systemic psoriasis therapeutics market by small molecules – Market size and forecast 2017-2022 ($ bn)
Exhibit 26: Global systemic psoriasis therapeutics market by small molecules – Year-over-year growth 2018-2022 (%)
Exhibit 27: Global systemic psoriasis therapeutics market by biologics – Market size and forecast 2017-2022 ($ bn)
Exhibit 28: Global systemic psoriasis therapeutics market by biologics – Year-over-year growth 2018-2022 (%)
Exhibit 29: Market opportunity by product
Exhibit 30: Customer landscape
Exhibit 31: Global systemic psoriasis therapeutics market by region – Market share 2017-2022 (%)
Exhibit 32: Regional comparison
Exhibit 33: Global systemic psoriasis therapeutics market in Americas – Market size and forecast 2017-2022 ($ bn)
Exhibit 34: Global systemic psoriasis therapeutics market in Americas – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top three countries in Americas
Exhibit 36: Global systemic psoriasis therapeutics market in EMEA – Market size and forecast 2017-2022 ($ bn)
Exhibit 37: Global systemic psoriasis therapeutics market in EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top three countries in EMEA
Exhibit 39: Global systemic psoriasis therapeutics market in APAC – Market size and forecast 2017-2022 ($ bn)
Exhibit 40: Global systemic psoriasis therapeutics market in APAC – Year-over-year growth 2018-2022 (%)
Exhibit 41: Top three countries in APAC
Exhibit 42: Market opportunity
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: AbbVie overview
Exhibit 49: AbbVie – Business segments
Exhibit 50: AbbVie – Organizational developments
Exhibit 51: AbbVie – Geographic focus
Exhibit 52: AbbVie – Segment focus
Exhibit 53: AbbVie – Key offerings
Exhibit 54: Amgen overview
Exhibit 55: Amgen – Business Segments
Exhibit 56: Amgen – Organizational developments
Exhibit 57: Amgen – Geographic focus
Exhibit 58: Amgen – Segment focus
Exhibit 59: Amgen – Key offerings
Exhibit 60: Celgene overview
Exhibit 61: Celgene – Business segments
Exhibit 62: Celgene – Organizational developments
Exhibit 63: Celgene – Geographic focus
Exhibit 64: Celgene – Segment focus
Exhibit 65: Celgene – Key offerings
Exhibit 66: Johnson & Johnson overview
Exhibit 67: Johnson & Johnson – Business segments
Exhibit 68: Johnson & Johnson – Organizational developments
Exhibit 69: Johnson & Johnson – Geographic focus
Exhibit 70: Johnson & Johnson – Segment focus
Exhibit 71: Johnson & Johnson – Key offerings
Note: Product cover images may vary from those shown
New Report Released: - Global Systemic Psoriasis Therapeutics Market 2018-2022
The author of the report recognizes the following companies as the key players in the global systemic psoriasis therapeutics market: AbbVie, Amgen, Celgene, and Johnson & Johnson.
Commenting on the report, an analyst from the research team said: “One trend affecting this market is the rise in cost of systemic psoriasis therapy. The cost of the treatment depends on the severity of the disease. The first line of treatment is usually a systemic agent, and if ineffective a more potent systemic agent is used which increases the cost of treatment.”
According to the report, one driver influencing this market is the need for affordable therapies. Topical treatments are most often purchased medication. Biologics are the most expensive medication and treatment failure can increase the medication cost.
Further, the report states that one challenge affecting this market is the patent expiry of drugs. The patent for major biologics for systemic psoriasis therapy have expired, which increases chances of adoption of biosimilars.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The author of the report recognizes the following companies as the key players in the global systemic psoriasis therapeutics market: AbbVie, Amgen, Celgene, and Johnson & Johnson.
Commenting on the report, an analyst from the research team said: “One trend affecting this market is the rise in cost of systemic psoriasis therapy. The cost of the treatment depends on the severity of the disease. The first line of treatment is usually a systemic agent, and if ineffective a more potent systemic agent is used which increases the cost of treatment.”
According to the report, one driver influencing this market is the need for affordable therapies. Topical treatments are most often purchased medication. Biologics are the most expensive medication and treatment failure can increase the medication cost.
Further, the report states that one challenge affecting this market is the patent expiry of drugs. The patent for major biologics for systemic psoriasis therapy have expired, which increases chances of adoption of biosimilars.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
- AbbVie
- Amgen
- Celgene
- Johnson & Johnson
Note: Product cover images may vary from those shown
LOADING...
